Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Liabilities and Shareholders Equity (2016 - 2025)

Regenxbio has reported Liabilities and Shareholders Equity over the past 12 years, most recently at $453.0 million for Q4 2025.

  • Quarterly results put Liabilities and Shareholders Equity at $453.0 million for Q4 2025, down 2.78% from a year ago — trailing twelve months through Dec 2025 was $2.1 billion (down 6.11% YoY), and the annual figure for FY2025 was $453.0 million, down 2.78%.
  • Liabilities and Shareholders Equity for Q4 2025 was $453.0 million at Regenxbio, down from $525.2 million in the prior quarter.
  • Over the last five years, Liabilities and Shareholders Equity for RGNX hit a ceiling of $1.1 billion in Q4 2021 and a floor of $453.0 million in Q4 2025.
  • Median Liabilities and Shareholders Equity over the past 5 years was $658.1 million (2023), compared with a mean of $709.9 million.
  • Biggest five-year swings in Liabilities and Shareholders Equity: skyrocketed 89.56% in 2021 and later tumbled 31.12% in 2023.
  • Regenxbio's Liabilities and Shareholders Equity stood at $1.1 billion in 2021, then fell by 25.19% to $833.3 million in 2022, then tumbled by 31.12% to $574.0 million in 2023, then fell by 18.81% to $466.0 million in 2024, then decreased by 2.78% to $453.0 million in 2025.
  • The last three reported values for Liabilities and Shareholders Equity were $453.0 million (Q4 2025), $525.2 million (Q3 2025), and $581.0 million (Q2 2025) per Business Quant data.